Scientific American2h
What Is Journavx, the New Opioid-Free Painkiller from Vertex?
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
Too Old to Operate11h
Exploring taVNS as a Treatment for CIPN
The following is a summary of “Feasibility of trancutaneous auricular vagus nerve stimulation in Black and Hispanic/Latino people with peripheral neuropathy,” published in the January 2025 issue of ...
Pharmaceutical Technology on MSN13h
FDA approves Vertex’s acute pain treatment Journavx
The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.
Healthline8d
Is TENS Effective for Managing Diabetic Neuropathy Pain?
A 2010 study examined three randomized controlled trials involving 78 people with symptomatic diabetic peripheral neuropathy. Researchers found that average pain scores were significantly reduced ...
Zacks.com on MSN6h
VRTX Gets FDA Nod for Non-Opioid Pain Drug Journavx, Shares Up
The FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.
Vitamin B6 is essential – but too much can be toxic. Here’s what to know to stay safe
Vitamin B6 can cause permanent damage to nerves. Studies have shown symptoms improved when the person stopped taking the ...
Many cancer patients experience nerve pain from chemo
Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.
Too Old to Operate2d
Association of hs-cTnT With Diabetic Lower Extremity Disease
The following is a summary of “Correlation between high-sensitivity cardiac troponin levels in diabetic patients’ serum and ...
Vertex Pharmaceuticals’ Suzetrigine: A Promising Opioid Alternative in Pain Management
Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...